SMT201500056B - Derivati 4-(metilamminofenossi)piridin-3-il benzammidici per il trattamento del cancro - Google Patents
Derivati 4-(metilamminofenossi)piridin-3-il benzammidici per il trattamento del cancroInfo
- Publication number
- SMT201500056B SMT201500056B SM201500056T SM201500056T SMT201500056B SM T201500056 B SMT201500056 B SM T201500056B SM 201500056 T SM201500056 T SM 201500056T SM 201500056 T SM201500056 T SM 201500056T SM T201500056 B SMT201500056 B SM T201500056B
- Authority
- SM
- San Marino
- Prior art keywords
- methylaminophenoxy
- pyridin
- cancer treatment
- benzamide derivatives
- benzamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38939310P | 2010-10-04 | 2010-10-04 | |
| PCT/JP2011/073165 WO2012046825A1 (en) | 2010-10-04 | 2011-10-03 | 4- (methylaminophenoxy) pyrdin- 3 - yl - benzamide derivatives for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SMT201500056B true SMT201500056B (it) | 2015-05-05 |
Family
ID=44872549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM201500056T SMT201500056B (it) | 2010-10-04 | 2015-03-09 | Derivati 4-(metilamminofenossi)piridin-3-il benzammidici per il trattamento del cancro |
Country Status (29)
| Country | Link |
|---|---|
| US (7) | US8946437B2 (zh) |
| EP (1) | EP2624833B1 (zh) |
| JP (1) | JP5715690B2 (zh) |
| KR (1) | KR101797797B1 (zh) |
| CN (1) | CN103189061B (zh) |
| AR (1) | AR083287A1 (zh) |
| AU (1) | AU2011313236B2 (zh) |
| BR (1) | BR112013007841B1 (zh) |
| CA (1) | CA2813153C (zh) |
| CO (1) | CO6660459A2 (zh) |
| DK (1) | DK2624833T3 (zh) |
| EA (1) | EA021627B1 (zh) |
| ES (1) | ES2526574T3 (zh) |
| HK (1) | HK1187540A1 (zh) |
| HR (1) | HRP20141237T1 (zh) |
| IL (1) | IL225520A (zh) |
| MX (1) | MX2013003589A (zh) |
| MY (1) | MY157563A (zh) |
| NZ (1) | NZ609151A (zh) |
| PL (1) | PL2624833T3 (zh) |
| PT (1) | PT2624833E (zh) |
| RS (1) | RS53749B1 (zh) |
| SG (1) | SG189146A1 (zh) |
| SI (1) | SI2624833T1 (zh) |
| SM (1) | SMT201500056B (zh) |
| TW (1) | TWI526431B (zh) |
| UA (1) | UA110037C2 (zh) |
| WO (1) | WO2012046825A1 (zh) |
| ZA (1) | ZA201302332B (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA021627B1 (ru) * | 2010-10-04 | 2015-07-30 | Оцука Фармасьютикал Ко., Лтд. | Производные 4-(метиламинофенокси)пиридин-3-илбензамида для лечения рака |
| JP6066806B2 (ja) * | 2012-04-03 | 2017-01-25 | 大塚製薬株式会社 | 医薬 |
| TW202102216A (zh) | 2019-03-25 | 2021-01-16 | 日商大塚製藥股份有限公司 | 抗腫瘤組合物 |
| CN118005541A (zh) * | 2023-12-13 | 2024-05-10 | 张家港格瑞特化学有限公司 | 一种双牛磺酸盐及其制备方法与应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6022884A (en) * | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
| JP2001089412A (ja) | 1999-09-22 | 2001-04-03 | Otsuka Pharmaceut Co Ltd | ベンゼン誘導体またはその医薬的に許容される塩 |
| MX2007001215A (es) | 2004-08-06 | 2007-04-17 | Otsuka Pharma Co Ltd | Compuestos aromaticos. |
| PT1957073E (pt) * | 2005-12-05 | 2014-05-12 | Otsuka Pharma Co Ltd | Medicamento |
| UA95978C2 (ru) | 2006-10-02 | 2011-09-26 | Оцука Фармас'Ютікел Ко., Лтд. | Ингибитор активации stat3/5 |
| EA021627B1 (ru) * | 2010-10-04 | 2015-07-30 | Оцука Фармасьютикал Ко., Лтд. | Производные 4-(метиламинофенокси)пиридин-3-илбензамида для лечения рака |
| TW202102216A (zh) * | 2019-03-25 | 2021-01-16 | 日商大塚製藥股份有限公司 | 抗腫瘤組合物 |
-
2011
- 2011-10-03 EA EA201390323A patent/EA021627B1/ru unknown
- 2011-10-03 CA CA2813153A patent/CA2813153C/en active Active
- 2011-10-03 WO PCT/JP2011/073165 patent/WO2012046825A1/en active Application Filing
- 2011-10-03 EP EP20110773326 patent/EP2624833B1/en active Active
- 2011-10-03 JP JP2013515439A patent/JP5715690B2/ja active Active
- 2011-10-03 CN CN201180047707.2A patent/CN103189061B/zh active Active
- 2011-10-03 NZ NZ60915111A patent/NZ609151A/en unknown
- 2011-10-03 BR BR112013007841-3A patent/BR112013007841B1/pt active IP Right Grant
- 2011-10-03 AU AU2011313236A patent/AU2011313236B2/en active Active
- 2011-10-03 KR KR1020137008052A patent/KR101797797B1/ko active IP Right Grant
- 2011-10-03 UA UAA201303865A patent/UA110037C2/uk unknown
- 2011-10-03 SG SG2013023148A patent/SG189146A1/en unknown
- 2011-10-03 US US13/877,276 patent/US8946437B2/en active Active
- 2011-10-03 TW TW100135750A patent/TWI526431B/zh active
- 2011-10-03 SI SI201130409T patent/SI2624833T1/sl unknown
- 2011-10-03 MY MYPI2013001147A patent/MY157563A/en unknown
- 2011-10-03 PL PL11773326T patent/PL2624833T3/pl unknown
- 2011-10-03 RS RS20150024A patent/RS53749B1/en unknown
- 2011-10-03 PT PT11773326T patent/PT2624833E/pt unknown
- 2011-10-03 MX MX2013003589A patent/MX2013003589A/es active IP Right Grant
- 2011-10-03 AR ARP110103657 patent/AR083287A1/es unknown
- 2011-10-03 ES ES11773326.1T patent/ES2526574T3/es active Active
- 2011-10-03 DK DK11773326T patent/DK2624833T3/en active
-
2013
- 2013-03-28 ZA ZA2013/02332A patent/ZA201302332B/en unknown
- 2013-04-02 IL IL225520A patent/IL225520A/en active IP Right Grant
- 2013-04-16 CO CO13097703A patent/CO6660459A2/es unknown
-
2014
- 2014-01-22 HK HK14100670.1A patent/HK1187540A1/zh unknown
- 2014-12-17 US US14/574,102 patent/US20150105432A1/en not_active Abandoned
- 2014-12-18 HR HRP20141237AT patent/HRP20141237T1/hr unknown
-
2015
- 2015-03-09 SM SM201500056T patent/SMT201500056B/xx unknown
-
2016
- 2016-11-28 US US15/362,561 patent/US20170298023A1/en not_active Abandoned
-
2018
- 2018-05-02 US US15/969,690 patent/US20180265471A1/en not_active Abandoned
-
2019
- 2019-06-13 US US16/440,924 patent/US20200031773A1/en not_active Abandoned
-
2020
- 2020-09-30 US US17/039,731 patent/US20210017134A1/en not_active Abandoned
-
2022
- 2022-12-30 US US18/148,672 patent/US20230139808A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SMT201500168B (it) | Derivati di piperidinone come inibitori di mdm2 per il trattamento del cancro | |
| CY2022027I2 (el) | Παραγωγα βενζιμιδαζολο-προλινης | |
| SMT201700053B (it) | Derivato del cicloalcano | |
| SMT201600198B (it) | Derivati di 1,2,4-triazina-4-ammina | |
| SMT201700003B (it) | Didropiridoni come inibitori del fattore xia | |
| SMT201600298B (it) | Derivati n3-sostituiti-n1-solfonil-5- fluoropirimidinone | |
| SMT201500270B (it) | Derivati di pirrolotriazinone come inibitori di pi3k | |
| DK2818482T3 (da) | Farmaceutisk sammensætning til behandling af cancer | |
| DK2824114T3 (da) | Farmaceutisk sammensætning til behandling af cancer | |
| DK2897620T3 (da) | Fremgangsmåde til behandling af cancer | |
| BR112014007603A2 (pt) | métodos de tratamento do câncer | |
| FI20125146A (fi) | Selluloosamassan esikäsittelymenetelmä | |
| DK2707030T3 (da) | Cancerbehandlinger | |
| BR112014012880A2 (pt) | tratamento imunogênico do câncer | |
| BR112014028424A2 (pt) | compostos de pirimidina para o tratamento de câncer | |
| SMT201600235B (it) | Predittori per il trattamento del cancro | |
| SMT201700056B (it) | Fosfaplatine e relativo utilizzo per il trattamento di cancro | |
| HK1212617A1 (zh) | 白癜風的治療 | |
| BR112013011659A2 (pt) | métodos de tratamento do câncer | |
| DK2944327T3 (da) | Ultraviolet sterilisator | |
| SMT201400080B (it) | Derivati di pirazinoossazepina | |
| SMT201600405B (it) | Derivati di arilalchilamminocarbossammide fluorurati | |
| DK2892535T3 (da) | Fremgangsmåde til adjuverende cancerbehandling | |
| SMT201600296B (it) | Lapatinib per il trattamento del cancro | |
| FI20135757A (fi) | Säädettävä kenkäteline |